Moderna’s “stunning” second vaccine

America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports

Biotechnology firm Moderna is celebrating after “tremendously exciting” preliminary results from late-stage trials of its Covid-19 vaccine, says Sarah Knapton in The Daily Telegraph. So far, only five people in the trial who received the jab have contracted the virus, compared with 90 who received a placebo, implying that it is nearly 95%-effective in preventing infection. That would make it “even more effective than either the Pfizer/BioNTech or Russian jab”. The trials suggest that it can even protect “the elderly and vulnerable who are most at risk”, with no one who has received the jab developing severe Covid-19 yet (compared with 11 from the placebo group).

Moderna’s success is “stunning”, says Robert Cyran on Breakingviews. Not only is it highly effective, but side effects are also “moderate”. More importantly, it can be stored in a conventional freezer for six months, and in a fridge up to 30 days, making it much easier to distribute than Pfizer’s vaccine, which must be “kept far colder, complicating distribution”. This is particularly good news for emerging markets, who not only lack expensive storage facilities, but will also benefit from the fact that richer countries have ordered far more doses than they need. The US alone ordered 600 million doses.

Vindication after a volatile year

This is “great news”, says Lex in the Financial Times. The data also brings “vindication for one of the sector’s most divisive companies”. After a “record-setting” initial public offering in December 2018, its shares spent much of 2019 trading below its opening price. However, the coronavirus pandemic has put its work on messenger-RNA, which prompts the body to make its own medicine, “back into focus”. Indeed, there are hopes that the Covid-19 jab may represent “proof of concept” for other Moderna treatments, including a personalised cancer vaccine. So, it’s no surprise that its shares have risen by 390% this year. Thanks to its latest success, Moderna should easily find enough money to develop its other vaccines, says Charley Grant in The Wall Street Journal. Its $40bn valuation means it can raise funds by selling shares and it also has $4bn in cash on the books. Selling even 500 million doses of vaccine at $200 each would translate into $10bn, which should come with “attractive profit margins” as Moderna’s decision not to seek a partner means that “it won’t have to share those profits”.

AstraZeneca should also be happy, says Nils Pratley in the Guardian. Moderna’s trial suggests that its own jab, developed in conjunction with Oxford University, will report similarly good news next month. What’s more, it stands to benefit from the fact that it “made a very good bet” when it invested in Moderna as long ago as 2013, back when it was a “three-year-old biotechnology tiddler”. As a result, its 7.6% stake, which cost just $380m, is now worth $2.9bn – a “very decent” return.

Recommended

The Federal Reserve wants markets to fall – here’s what that means for investors
Stockmarkets

The Federal Reserve wants markets to fall – here’s what that means for investors

The Federal Reserve’s primary mandate is to keep inflation down, and lower asset prices help with that. So, asks Dominic Frisby – just how low will st…
25 May 2022
Flexible working: don't rush your staff back the office
Small business

Flexible working: don't rush your staff back the office

The government is urging people to get back to the office. But there are good reasons for many small businesses to embrace flexible working.
25 May 2022
Let’s adjust to living with Covid and get Britain back to work
UK Economy

Let’s adjust to living with Covid and get Britain back to work

The Covid-19 era is over, leaving a stagnant and lethargic workforce in its wake. It’s time to wake up, says Matthew Lynn.
25 May 2022
Should you be worried about energy windfall tax proposals?
Energy

Should you be worried about energy windfall tax proposals?

Calls have been growing for a windfall tax on UK oil and gas producers. It's a popular idea, but is it a good one? And what does it mean for investors…
24 May 2022

Most Popular

Everything is collapsing at once – here’s what to do about it
Investment strategy

Everything is collapsing at once – here’s what to do about it

Equity and bond markets are crashing, while inflation destroys the value of cash. Merryn Somerset Webb looks at where investors can turn to protect th…
23 May 2022
Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Three high-quality FTSE 100 shares going cheap
Share tips

Three high-quality FTSE 100 shares going cheap

As stockmarkets continue to fall, bargains are starting to appear, says Rupert Hargreaves. Here, he picks three high-quality FTSE 100 shares that are …
23 May 2022